Myelodysplastic Syndrome — Trials

Myelodysplastic Syndrome — Trials · CancerIndex

Clinical trials

Registered studies

1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 336
Recruiting: 196
Ph III recruiting: 9
Growth YoY: +2.1%
Industry share: 20%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 33.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (307)

clinicaltrialsPublishedShowing 101–150 of 442 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02610777	An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)	completed	Phase 2	120	Millennium Pharmaceuticals, Inc.INDUSTRY	12	Sep 19, 2022	clinicaltrials
NCT01119066	HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies	completed	Phase 2	422	Memorial Sloan Kettering Cancer Center